icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
qpRNzg8NB6a3e4HB
Listen
